@article{ref1,
title="Safety of non-therapeutic atomoxetine exposures-a national poison data system study",
journal="Human psychopharmacology",
year="2013",
author="Monte, Andrew A. and Ceschi, Alessandro and Bodmer, Michael",
volume="28",
number="5",
pages="471-476",
abstract="AIMS: This study's objective is to assess the safety of non-therapeutic atomoxetine exposures reported to the US National Poison Database System (NPDS). METHODS: This is a retrospective database study of non-therapeutic single agent ingestions of atomoxetine in children and adults reported to the NPDS between 2002 and 2010. RESULTS: A total of 20 032 atomoxetine exposures were reported during the study period, and 12 370 of these were single agent exposures. The median age was 9 years (interquartile range 3, 14), and 7380 were male (59.7%). Of the single agent exposures, 8813 (71.2%) were acute exposures, 3315 (26.8%) were acute-on-chronic, and 166 (1.3%) were chronic. In 10 608 (85.8%) cases, exposure was unintentional, in 1079 (8.7%) suicide attempts, and in 629 (5.1%) cases abuse. Of these cases, 3633 (29.4 %) were managed at health-care facilities. Acute-on-chronic exposure was associated with an increased risk of a suicidal reason for exposure compared with acute ingestions (odds ratio 1.44, 95% confidence interval 1.26-1.65). Most common clinical effects were drowsiness or lethargy (709 cases; 5.7%), tachycardia (555; 4.5%), and nausea (388; 3.1%). Major toxicity was observed in 21 cases (seizures in nine (42.9%), tachycardia in eight (38.1%), coma in six (28.6%), and ventricular dysrhythmia in one case (4.8%)). CONCLUSIONS: Non-therapeutic atomoxetine exposures were largely safe, but seizures were rarely observed. Copyright © 2013 John Wiley & Sons, Ltd.<p /> <p>Language: en</p>",
language="en",
issn="0885-6222",
doi="10.1002/hup.2334",
url="http://dx.doi.org/10.1002/hup.2334"
}